FDA WARNING_LETTER - Altru Telehealth, LLC dba Altru Telehealth - March 01, 2026

On June 8, 2026, the FDA issued a warning letter to Altru Telehealth, LLC following a review of the company’s website conducted in March 2026. The agency identified significant violations regarding the marketing and promotion of compounded drug products, specifically those containing semaglutide and tirzepatide. The primary violations involve false and misleading claims that characterize compounded drugs as FDA-approved or equivalent to brand-name medications like Wegovy and Mounjaro. Additionally, the FDA noted that Altru Telehealth incorrectly labeled its partner compounding pharmacies as "FDA-approved" or "FDA-licensed." Under the Federal Food, Drug, and Cosmetic Act, the FDA does not approve compounded drugs for safety and effectiveness, nor does it grant approval or licensing designations to compounding facilities. These misrepresentations constitute misbranding and violate federal law regarding the introduction of drug products into the market. To rectify these issues, the FDA requires Altru Telehealth to submit a written response within 15 business days detailing the root causes of the violations and the specific corrective actions taken. Required actions include identifying the entities producing the drugs, providing sample labeling, and removing all misleading claims from their website. Failure to comply may result in legal action, including product seizures or injunctions.